Tyrosine kinase inhibitors that target pro-angiogenic pathways improve progression-free and overall survival in patients with metastatic kidney cancer and were thus tested in the adjuvant setting in studies published this past year. 2016 also saw the emergence of new inhibitors of pro-angiogenic pathways that might represent the next step in kidney cancer therapy.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Heterogeneity of tumor microenvironment is associated with clinical prognosis of non-clear cell renal cell carcinoma: a single-cell genomics study
Cell Death & Disease Open Access 11 January 2022
-
Multi-omics analysis of tumor angiogenesis characteristics and potential epigenetic regulation mechanisms in renal clear cell carcinoma
Cell Communication and Signaling Open Access 24 March 2021
-
Trends in the kidney cancer mortality-to-incidence ratios according to health care expenditures of 56 countries
Scientific Reports Open Access 14 January 2021
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Cancer Genome Atlas Research Network. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 499, 43–49 (2013).
Motzer, R. J. et al. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. Lancet Oncol. 16, 1473–1482 (2015).
Choueiri, T. K. et al. Cabozantinib versus everolimus in advanced renal-cell carcinoma. N. Engl. J. Med. 373, 1814–1823 (2015).
Haas, N. B. et al. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet 387, 2008–2016 (2016).
Ravaud, A. et al. Adjuvant sunitinib in high-risk renal-cell carcinoma after nephrectomy. N. Engl. J. Med. 375, 2246–2254 (2016).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT01599754 (2016).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT01235962 (2016).
Cho, H. et al. On-target efficacy of a HIF2alpha antagonist in preclinical kidney cancer models. Nature 539, 107–111 (2016).
Chen, W. et al. Targeting renal cell carcinoma with a HIF-2 antagonist. Nature 539, 112–117 (2016).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02293980 (2016).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
R.J.M. consults for Pfizer, Novartis, Eisai and Exelixis, and has received research funds for the institute for work with Pfizer, Genentech/Roche, Novartis, Eisai and Exelixis. C.H.L consults for Exelixis, and has received research funds for the institute for work with Eisai and Pfizer.
PowerPoint slides
Rights and permissions
About this article
Cite this article
Lee, CH., Motzer, R. The evolution of anti-angiogenic therapy for kidney cancer. Nat Rev Nephrol 13, 69–70 (2017). https://doi.org/10.1038/nrneph.2016.194
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneph.2016.194
This article is cited by
-
Heterogeneity of tumor microenvironment is associated with clinical prognosis of non-clear cell renal cell carcinoma: a single-cell genomics study
Cell Death & Disease (2022)
-
Multi-omics analysis of tumor angiogenesis characteristics and potential epigenetic regulation mechanisms in renal clear cell carcinoma
Cell Communication and Signaling (2021)
-
Trends in the kidney cancer mortality-to-incidence ratios according to health care expenditures of 56 countries
Scientific Reports (2021)
-
Modeling clear cell renal cell carcinoma and therapeutic implications
Oncogene (2020)
-
6-Gingerol stabilized the p-VEGFR2/VE-cadherin/β-catenin/actin complex promotes microvessel normalization and suppresses tumor progression
Journal of Experimental & Clinical Cancer Research (2019)
